Difference between revisions of "Non-small cell lung cancer, BRAF-mutated"
Jump to navigation
Jump to search
m |
m |
||
| Line 33: | Line 33: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928 | + | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928)] |
|2014-2015 | |2014-2015 | ||
|style="background-color:#91cf61"|Phase II (RT) | |style="background-color:#91cf61"|Phase II (RT) | ||
|- | |- | ||
|} | |} | ||
| − | ====Biomarker | + | ====Biomarker eligibility criteria==== |
*Biomarker: BRAF V600E | *Biomarker: BRAF V600E | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| Line 66: | Line 66: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928 | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928)] |
|2013-2015 | |2013-2015 | ||
|style="background-color:#91cf61"|Phase II (RT) | |style="background-color:#91cf61"|Phase II (RT) | ||
|- | |- | ||
|} | |} | ||
| − | ''All enrolled | + | ''All patients enrolled in this cohort had progressed on 1 to 3 prior regimens.'' |
| − | ====Biomarker | + | ====Biomarker eligibility criteria==== |
*Biomarker: BRAF V600E | *Biomarker: BRAF V600E | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
Revision as of 01:32, 2 May 2021
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN  AmitKulkarniMD
|
 |
Travis Osterman, DO, MS, FAMIA Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Advanced or metastatic disease, first-line
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Planchard et al. 2017 (BRF113928) | 2014-2015 | Phase II (RT) |
Biomarker eligibility criteria
- Biomarker: BRAF V600E
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed NCT01336634
Advanced or metastatic disease, previously treated, BRAF inhibitor-naive
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Planchard et al. 2016 (BRF113928) | 2013-2015 | Phase II (RT) |
All patients enrolled in this cohort had progressed on 1 to 3 prior regimens.
Biomarker eligibility criteria
- Biomarker: BRAF V600E
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. link to original article contains verified protocol link to PMC article PubMed NCT01336634